Clinical experience of adalimumab in the treatment of psoriasis - A 10-year journey in a tertiary dermatology centre

Sir,

Adalimumab is a recombinant human immunoglobulin monoclonal antibody, which inhibits tumor necrosis factor-alpha (TNFα). It is approved for use in moderate-to-severe psoriasis vulgaris and psoriatic arthritis by the United States Food and Drug Administration. Randomized control trials (RCTs) have shown that adalimumab is efficacious and well-tolerated, with efficacy maintained over more than 5 years of treatment. However, conducted RCTs have strict inclusion, exclusion, and predefined continuation and discontinuation criteria, making it difficult to extrapolate the data for use in real-world daily practice. This retrospective study aims to examine the safety and efficacy of adalimumab in daily practice over its 10-year use in psoriasis patients in a tertiary dermatology centre.

The case records of psoriasis patients who were prescribed adalimumab were retrieved and analyzed from the institutional...
Letters to the Editor

electronic database from September 2006 to August 2016. Demographic data and disease specific data collected included age, sex, disease duration, prior systemic or biologic use, baseline screening, psoriasis area and severity index (PASI) score, body surface area (BSA), and adverse events.

All patients underwent baseline full blood count, creatinine, liver function, chest radiograph, hepatitis B and C screening, with Mantoux and/or T-SpOT.TB test.

Patients with chronic plaque psoriasis and generalized pustular psoriasis were studied. Patients with pure psoriatic arthritis were not included. Treatment aim was to improve moderate to severe chronic plaque psoriasis. Biologics were indicated for patients with moderate-to-severe plaque psoriasis (PASI >10 or BSA >10%) who failed to respond or had contraindications to standard systemic therapy or phototherapy. Adalimumab was dosed at 80 mg subcutaneously at week 0, followed by 40 mg at week 1, and 40 mg every-other-week. This study was approved by the local institutional ethics review committee.

The primary efficacy was determined at 16 weeks, in line with other studies comparing efficacy; further progress and adverse events were monitored in patient follow-up through their electronic medical records. Efficacy assessments included the proportion of patients achieving at least 75% reduction in PASI (PASI75) compared to baseline at week 16. PASI and BSA were not uniformly recorded after 16 weeks of treatment.

Baseline characteristics of patients were summarized using descriptive statistics. Wilcoxon signed-rank test was used to evaluate PASI and BSA scores at baseline and week 16. Statistical significance was set at P < 0.05. For safety evaluation, adverse effects of the treatment were summarized. Statistics were computed using Stata Version 14.1, StataCorp LP, USA.

Forty-five patients were enrolled, and background characteristics and demographics are summarized in Table 1. Mean treatment duration was 46.1 weeks. Thirty-three patients (73.3%) were no longer on adalimumab at the time of data collection, with 14 patients (42.4%) citing cost as the reason for stopping treatment.

There was a significant improvement in PASI score from mean PASI of 19.3 to 5.1 at 16 weeks (P < 0.001) [Figure 1]. BSA dropped from the baseline mean of 32.9 to 9.9 at week 16 (P < 0.001).

Eighteen patients (40%) had active psoriatic arthritis prior to treatment with adalimumab, and 16 of these (88.9%) had subjective improvement in joint pains while on adalimumab, although psoriatic arthritis disease activity scores and radiological response were not recorded.

Two patients with generalized pustular psoriasis were treated with adalimumab. One patient received acitretin, methotrexate, cyclosporine, and isotretinoin with suboptimal control prior to treatment with adalimumab. Baseline BSA was 70% and improved to 5% at week 16. The second patient failed cyclosporine with methotrexate therapy and BSA improved from 20% to 5% after 16 weeks of adalimumab.

Prior and concurrent therapy with adalimumab is described in Table 2. Twenty-eight patients (62.2%) were biologic-naïve at the start of adalimumab therapy. Those who had previous biologic therapies are presented in Table 2. The number of patients who had received different biologics previously varied from 0 to 5. The difference in PASI75 at 16 weeks were not significant between biologic-naïve and nonbiologic-naïve patients (P = 0.060) [Figure 2].

Five patients (11.1%) stopped treatment due to side effects: these include urinary sepsis, sinusitis, pulmonary tuberculosis (TB), and pneumonia [Table 3]; of note, two patients developed TB. Both patients were self-funded on adalimumab, one being an Indian male who restarted adalimumab after 6 months of anti-TB treatment, and the other a Chinese female who discontinued adalimumab after anti-TB treatment. Three patients had reactive T-SPOT.TB test (after initial negative test) after treatment with adalimumab and were treated with isoniazid for latent tuberculosis infection. It is important to screen for TB, especially in South-East Asia, where TB risk is high with an estimated incidence of 36.9 per 100,000 population. Compared to other biologics in our centre (unpublished data), 2 out of 10 patients were treated for latent tuberculosis infection prior to initiation of infliximab, and 11 out of 99 patients were treated for latent tuberculosis infection prior to treatment with ustekinumab. None of these patients developed pulmonary TB while on respective biologic treatment. As part of our biologic guidelines, we screen all patients on biologics annually with an interferon gamma release assay such as T-SPOT.TB blood test.

We were unable to find any previous reports reviewing the safety and efficacy of adalimumab in the treatment of psoriasis patients in Singapore. Our results show that 77.8% of the patients achieved PASI75 at 16 week of therapy, which is similar to other published reports. One patient has been receiving adalimumab for 7.9 years, and is currently still on adalimumab with good response.

---

**Table 1: Patient characteristics (n=45)**

| Characteristics                        | Total, n (%) |
|----------------------------------------|--------------|
| Mean age in years (range)              | 46.4 (19.0-71.0) |
| Sex                                     |              |
| Male                                    | 32 (71.1)    |
| Female                                  | 13 (28.9)    |
| Race                                    |              |
| Chinese                                 | 32 (71.1)    |
| Malay                                   | 5 (11.1)     |
| Indian                                  | 6 (13.3)     |
| Caucasian                               | 2 (4.4)      |
| Type of psoriasis                       |              |
| Psoriasis                               | 43 (93.5)    |
| Generalized pustular psoriasis          | 2 (4.3)      |
| Psoriatic arthritis                     | 18 (40.0)    |
| Therapy status at analysis              |              |
| Active                                  | 12 (26.7)    |
| Discontinued                            | 33 (73.3)    |
| Reasons for adalimumab discontinuation  |              |
| Cost                                    | 14 (42.4)    |
| Secondary failure                       | 8 (24.2)     |
| Switch to another biologic              | 2 (6.1)      |
| Defaulted                               | 3 (9.1)      |
| Other                                   | 6 (18.2)     |
Overall, adalimumab proved to be relatively safe and generally well tolerated. It is important to screen for TB, especially in South-East Asia. All patients in our centre are screened annually with an interferon gamma release assay test.

Two of our patients with generalized pustular psoriasis who failed conventional therapy were treated successfully with adalimumab. Anti-TNFα therapy in psoriasis has been associated with worsening of psoriasis, erythrodermic flare, and development of palmoplantar pustulosis, but this was not observed in our study.1

Eight (15.6%) patients stopped adalimumab due to lack of efficacy, and the mean treatment duration was 24 weeks for nonresponders. These rates are similar to other randomized as well as open-label studies.2

Limitations to this study include its retrospective nature, no control group, and small study cohort. The PASI score was not uniformly recorded at every subsequent visit, and therefore, we were unable to compare efficacy with prolonged treatment. Adalimumab antibodies were not studied.
In conclusion, we demonstrate that adalimumab is effective and safe in the treatment of psoriasis and suggest important parameters to screen and monitor for in our population.

Acknowledgement
We acknowledge and thank Ms. Virlynn Tan, biostatistician, Research Department, National Skin Centre, for her statistical input.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

Wai Man Mandy Chan, Hazel Hweeboon Oon, Wei‑Sheng Chong
Department of Dermatology, National Skin Centre, 308205 Singapore

Correspondence: Dr. Wai Man Mandy Chan, Department of Dermatology, National Skin Centre, 1 Mandalay Road, 308205 Singapore. E‑mail: mandychan@nsc.com.sg

References
1. Menter A, Thaçi D, Papp KA, Wu JJ, Bereswill M, Teixeira HD, et al. Five‑year analysis from the ESPRIT 10‑year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. J Am Acad Dermatol 2015;73:410‑9.e6.
2. Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double‑blind, randomized controlled trial and open‑label extension study. J Am Acad Dermatol 2006;55:598‑606.
3. Ministry of Health Communicable Diseases Surveillance in Singapore; 2014. Available from: https://www.moh.gov.sg/content/dam/moh_web/Pубlications/Reports/2015/HIV‑AIDS%20STIs%20Tuberculosis%20Leprosy.pdf. [Last accessed on 2017 May 28].
4. Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor‑α inhibitors: The Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol 2012;67:e179‑85.
5. Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D. Adalimumab for psoriasis in Greece: Clinical experience in a tertiary referral centre. J Eur Acad Dermatol Venereol 2012;26:1298‑303.

This is an open access article distributed under the terms of the Creative Commons Attribution‑NonCommercial‑ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non‑commercially, as long as the author is credited and the new creations are licensed under the identical terms.